US Executive Compensation Proxy SEC Filings — June 04, 2026

04-06-2026

Advanced Biomed Inc. (ADVB) filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on June 30, 2026. The Board recommends voting FOR the election of five director nominees, FOR the advisory vote on executive compensation, ONE YEAR for the frequency of future advisory votes, FOR the ratification of WWC, P.C. as independent auditor, and FOR adjournment if needed. As of the record date (May 29, 2026), there were 1,652,133 shares of common stock outstanding and entitled to vote.

• · The Annual Meeting will be held in person at No. 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan on June 30, 2026 at 10:00 a.m. Eastern Time.
• · A quorum requires a majority of outstanding shares present in person or by proxy.
• · Directors are elected by a plurality of votes cast; broker non-votes have no effect on Proposal 1.
• · Proposal 2 (advisory vote on executive compensation) requires a majority of votes cast for approval.
• · Proposal 3 (frequency) will be decided by the option receiving the most votes among one, two, or three years.
• · Proposal 4 (ratification of auditor) and Proposal 5 (adjournment) require a majority of votes cast in favor.
• · Broker non-votes will be counted for quorum but not for non-routine proposals (Proposals 1, 2, 3, 5).
• · Proxies may be revoked by submitting a later-dated proxy, written revocation, or voting in person.
• · Final voting results will be filed on Form 8-K within four business days after the meeting.
• · Xiaomin Chen has over 20 years of experience in AI and fintech, previously worked at Google Inc.
• · Mingze Yin has over 11 years of financial and investment banking experience.
• · Jing Zhang has more than 25 years of financial management experience.
• · Cheang I Kei has experience in corporate governance and legal management.
• · Mingyue Cai is also an independent director nominee.

04-06-2026

Akari Therapeutics Plc filed a DEF 14A proxy statement for its 2026 Annual General Meeting, seeking shareholder approval on 18 resolutions including re-appointment of statutory auditor HaysMac LLP, advisory say-on-pay for named executive officers, and authorizations for multiple equity issuances under Nasdaq Listing Rules. The company, a pre-revenue biotechnology firm, is pursuing equity financings to support its operating plan, with resolutions to allot up to 4,000,000,000,000 ordinary shares (corresponding to 50,000,000 ADSs) and to disapply statutory pre-emption rights through June 30, 2031. No financial results or period-over-period comparisons are provided in this filing.

• · No tax services were provided by BDO during fiscal years 2024 and 2025.
• · Resolution 14 seeks approval for issuance of shares under the ELOC Purchase Agreement with White Lion Capital for up to $25,000,000 in aggregate gross purchase price.
• · Resolution 15 seeks approval for issuance of warrants to purchase up to 4,411,764 ADSs and 117,647 placement agent ADSs.
• · Resolution 16 seeks approval for a potential change-of-control private placement under Nasdaq Rule 5635(b).
• · Resolution 17 authorizes allotment of up to 4,000,000,000,000 ordinary shares (50,000,000 ADSs) through June 30, 2031.
• · Resolution 18 seeks to disapply statutory pre-emption rights for cash issuances.
• · The company is pre-revenue and intends to seek additional fundraisings to support R&D activities.

04-06-2026

DXC Technology Company filed its definitive proxy statement (DEF 14A) on June 4, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on July 21, 2026. The meeting will include the election of 9 director nominees, ratification of Deloitte & Touche LLP as auditor for fiscal year ending March 31, 2027, a non-binding advisory vote on named executive officer compensation, and approval of term extensions and share increases under the 2017 Omnibus Incentive Plan and the 2017 Non-Employee Director Incentive Plan. The filing highlights the company's focus on AI-driven transformation and improving execution to achieve sustainable and profitable growth.

• · The annual meeting will be held virtually on July 21, 2026 at 8:00 a.m. Eastern Time.
• · Stockholders of record as of May 28, 2026 are entitled to vote.
• · Proposals include ratification of Deloitte & Touche LLP as auditor for fiscal year ending March 31, 2027.
• · Proposals include approval of term extension and share increase under the 2017 Omnibus Incentive Plan and the 2017 Non-Employee Director Incentive Plan.
• · The proxy statement was first made available to stockholders on or about June 4, 2026.

04-06-2026

Decoy Therapeutics Inc. filed a definitive proxy statement (DEF 14A) on June 4, 2026, for its 2026 Annual Meeting of Stockholders to be held virtually on July 14, 2026. The meeting will include the election of three Class II directors, a non-binding advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor for fiscal year 2026. As of the record date of May 22, 2026, there were 531,968 shares of common stock outstanding and entitled to vote.

• · The annual meeting will be held virtually via live audio webcast at https://web.viewproxy.com/dcoy/2026.
• · Stockholders must register by 11:59 PM CT on July 12, 2026 to attend and vote.
• · The company is using the 'Notice and Access' method to distribute proxy materials via the Internet.
• · Proposal 1: Election of three Class II directors to serve until the 2029 Annual Meeting.
• · Proposal 2: Non-binding advisory vote on named executive officer compensation.
• · Proposal 3: Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
• · The Board recommends voting 'FOR' all director nominees and 'FOR' Proposals 2 and 3.

04-06-2026

Ennis, Inc. filed its definitive proxy statement (DEF 14A) on June 4, 2026, for the Annual Meeting of Shareholders to be held on July 16, 2026. The meeting will include the election of three directors for three-year terms and one director for a partial term, ratification of the independent auditor, and a non-binding advisory vote on executive compensation. The company is utilizing e-proxy delivery to reduce costs and expedite shareholder access to materials.

• · The record date for shareholders entitled to vote is May 15, 2026.
• · The Annual Meeting will be held at the Midlothian Conference Center, One Community Circle, Midlothian, Texas 76065.
• · Shareholders can vote in person, by proxy over the internet, by telephone, or by mail if they request paper copies.

04-06-2026

BayFirst Financial Corp. held a Special Meeting to seek shareholder approval for the conversion/exchange of newly issued Series D and Series E preferred stock into common stock, which is necessary to close an April 28, 2026 private placement that raised $80M in gross proceeds to shore up the bank’s regulatory capital. However, the company disclosed significant financial pressures underlying the capital raise: a net loss of $22.9M for FY2025 and an additional net loss of $5.7M in Q1 2026, and the Bank’s capital ratios fell below ‘well-capitalized’ levels, prompting its primary regulator to threaten a formal enforcement action. The filing also outlines the appointment of Alfred T. Rogers, Jr. as President & CEO to lead a turnaround, and a planned public offering of up to 4,108,072 shares at $3.50 per share to existing shareholders at the same effective price as the private placement.

• · The private placement closed on April 28, 2026, issuing 4,000 shares of Series D and 4,000 shares of Series E, each at $10,000/share, for gross proceeds of $80M.
• · As of March 31, 2026, the Bank was not considered well-capitalized: Tier 1 leverage ratio of 6.54%, CET1 and Tier 1 capital ratios of 8.58% to risk-weighted assets, and total capital ratio of 9.84% to risk-weighted assets, leading the primary regulator to indicate it would pursue a formal enforcement action if capital was not improved.
• · The Company incurred a net loss of $22.9M for FY2025 and a net loss of $5.7M for Q1 2026.
• · The Company will commence a public offering of up to 4,108,072 shares of common stock at $3.50 per share exclusively to shareholders of record on May 12, 2026, at the same effective price as the private placement.
• · The Board unanimously recommends approval of all three proposals: Conversion Proposal, Articles Amendment Proposal (increase authorized common from 15M to 100M shares), and Adjournment Proposal.
• · The increase in authorized shares from 15,000,000 to 100,000,000 is required to complete the conversion/exchange of all Series D and Series E shares.

04-06-2026

Radnostix Inc. (formerly International Isotopes Inc.) filed its DEF 14A proxy statement for the 2026 Annual Meeting of Shareholders to be held on July 16, 2026. The Board recommends voting FOR the election of five director nominees, FOR the ratification of Haynie & Company as independent auditor for fiscal year 2026, and FOR the approval of the Radnostix 2026 Incentive Plan. The company had 529,130,353 shares of common stock outstanding as of the May 26, 2026 record date.

• · Annual Meeting to be held on July 16, 2026 at 2:00 p.m. local time at 4137 Commerce Circle, Idaho Falls, Idaho 83401.
• · Proxy materials available online at www.envisionreports.com/INIS.
• · Shareholders of record as of May 26, 2026 are entitled to vote.
• · The company's name appears to have changed from International Isotopes Inc. to Radnostix Inc. (referenced as 'Radnostix' or 'the Company').
• · Proposal 3 seeks approval of the Radnostix 2026 Incentive Plan, detailed in Appendix A.